{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T15:00:22Z","timestamp":1763564422863,"version":"3.41.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"name":"Project commissioned by the Pharmaceutical Administration Department of the National Health Commission"},{"name":"Chongqing Municipal Health Commission\u2014\u2014Senior Medical Talents Program of Chongqing for Young and Middle-aged"},{"name":"Chongqing Municipal Health Commission Office\u2014\u2014Chongqing Clinical Pharmacy Key Specialties Construction Project\uff08Respiratory medicine specialty\uff09"},{"name":"Chongqing innovative medical device application demonstration project","award":["CQEIC2024MDAD-051"],"award-info":[{"award-number":["CQEIC2024MDAD-051"]}]},{"name":"Bishan District Health Commission of Chongqing\u2014\u2014Bishan District of Chongqing Clinical Pharmacy Key Specialties Construction Project"},{"name":"Bishan District Science and Technology Bureau of Chongqing","award":["BSKJ2024066"],"award-info":[{"award-number":["BSKJ2024066"]}]},{"name":"Chongqing Clinical Pharmacy Key Specialties Construction Project"},{"name":"Senior Medical Talents Program of Chongqing for Young and Middle-aged"},{"name":"The project in Bishan Hospital of Chongqing\u2014\u2014Innovative team building based on evidence-based pharmacy","award":["BYKY-CX2023002"],"award-info":[{"award-number":["BYKY-CX2023002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Pharm"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1007\/s11096-025-01889-0","type":"journal-article","created":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T06:05:03Z","timestamp":1742450703000},"page":"863-872","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Cost-benefit analysis of pharmacist early active consultation in patients with multidrug-resistant bacteria in China"],"prefix":"10.1007","volume":"47","author":[{"given":"Xuefeng","family":"Shan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hongmei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lingxi","family":"Kong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youlan","family":"Shan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jie","family":"Dong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jinghui","family":"Gou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guili","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xin","family":"Xi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5986-9307","authenticated-orcid":false,"given":"Qian","family":"Du","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,3,20]]},"reference":[{"key":"1889_CR1","doi-asserted-by":"publisher","first-page":"dlad051","DOI":"10.1093\/jacamr\/dlad051","volume":"5","author":"T Holowka","year":"2023","unstructured":"Holowka T, van Duin D, Bartelt LA. Impact of childhood malnutrition and intestinal microbiota on MDR infections. JAC Antimicrob Resist. 2023;5:dlad051.","journal-title":"JAC Antimicrob Resist"},{"key":"1889_CR2","doi-asserted-by":"publisher","first-page":"13934","DOI":"10.1038\/s41598-022-18189-6","volume":"12","author":"CJ Kim","year":"2022","unstructured":"Kim CJ, Song KH, Choi NK, et al. Socioeconomic burden of pneumonia due to multidrug-resistant Acinetobacter baumannii and Pseudomonas aeruginosa in Korea. Sci Rep. 2022;12:13934.","journal-title":"Sci Rep"},{"key":"1889_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhepr.2023.100788","volume":"5","author":"N Verma","year":"2023","unstructured":"Verma N, Divakar Reddy PV, Vig S, et al. Burden, risk factors, and outcomes of multidrug-resistant bacterial colonisation at multiple sites in patients with cirrhosis. JHEP Rep. 2023;5: 100788.","journal-title":"JHEP Rep"},{"key":"1889_CR4","doi-asserted-by":"publisher","first-page":"1364","DOI":"10.1016\/j.cmi.2024.07.005","volume":"30","author":"X Liu","year":"2024","unstructured":"Liu X, Liu X, Jin C, et al. Prediction models for diagnosis and prognosis of the colonization or infection of multidrug-resistant organisms in adults: a systematic review, critical appraisal, and meta-analysis. Clin Microbiol Infect. 2024;30:1364\u201373.","journal-title":"Clin Microbiol Infect"},{"key":"1889_CR5","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1016\/j.arcmed.2021.09.002","volume":"52","author":"M Bassetti","year":"2021","unstructured":"Bassetti M, Vena A, Giacobbe DR, et al. Management of infections caused by multidrug-resistant gram-negative pathogens: recent advances and future directions. Arch Med Res. 2021;52:817\u201327.","journal-title":"Arch Med Res"},{"key":"1889_CR6","doi-asserted-by":"publisher","first-page":"577","DOI":"10.2217\/fmb-2017-0236","volume":"13","author":"AL Byrne","year":"2018","unstructured":"Byrne AL, Fox GJ, Marais BJ. Better than a pound of cure: preventing the development of multidrug-resistant tuberculosis. Future Microbiol. 2018;13:577\u201388.","journal-title":"Future Microbiol"},{"key":"1889_CR7","doi-asserted-by":"publisher","first-page":"712","DOI":"10.3390\/antibiotics12040712","volume":"12","author":"DF Bavaro","year":"2023","unstructured":"Bavaro DF, De Gennaro N, Belati A, et al. Impact of a pro-active infectious disease consultation on the management of a multidrug-resistant organisms outbreak in a COVID-19 hospital: a three-months quasi-experimental study. Antibiotics (Basel). 2023;12:712.","journal-title":"Antibiotics (Basel)"},{"key":"1889_CR8","doi-asserted-by":"publisher","first-page":"2557","DOI":"10.2147\/IDR.S260525","volume":"13","author":"L Liu","year":"2020","unstructured":"Liu L, Liu B, Li W. Successful incidences of controlling multidrug-resistant, extensively drug-Resistant, and nosocomial infection Acinetobacter baumannii using antibiotic stewardship, infection control programs, and environmental cleaning at a Chinese university hospital. Infect Drug Resist. 2020;13:2557\u201370.","journal-title":"Infect Drug Resist"},{"key":"1889_CR9","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s12916-020-01893-3","volume":"19","author":"E Carr","year":"2021","unstructured":"Carr E, Bendayan R, Bean D, et al. Evaluation and improvement of the national early warning score (NEWS2) for COVID-19: a multi-hospital study. BMC Med. 2021;19:23.","journal-title":"BMC Med"},{"key":"1889_CR10","doi-asserted-by":"publisher","first-page":"763","DOI":"10.2147\/COPD.S359123","volume":"17","author":"PW Stone","year":"2022","unstructured":"Stone PW, Minelli C, Feary J, et al. \u201cNEWS2\u201d as an objective assessment of hospitalised COPD exacerbation severity. Int J Chron Obstruct Pulmon Dis. 2022;17:763\u201372.","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"1889_CR11","doi-asserted-by":"publisher","first-page":"1128219","DOI":"10.3389\/fphar.2023.1128219","volume":"14","author":"Q Du","year":"2023","unstructured":"Du Q, Xi X, Dong J, et al. The impact of pharmacist early active consultation (PEAC) on multidrug resistance organism treatment outcomes: a prospective historically controlled study. Front Pharmacol. 2023;14:1128219.","journal-title":"Front Pharmacol"},{"key":"1889_CR12","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.41408","volume":"6","author":"DL Dixon","year":"2023","unstructured":"Dixon DL, Johnston K, Patterson J, et al. Cost-effectiveness of pharmacist prescribing for managing hypertension in the United States. JAMA Netw Open. 2023;6: e2341408.","journal-title":"JAMA Netw Open"},{"key":"1889_CR13","doi-asserted-by":"publisher","first-page":"1163","DOI":"10.1007\/s11096-024-01749-3","volume":"46","author":"E Hurley","year":"2024","unstructured":"Hurley E, Byrne S, Walsh E, et al. Cost avoidance of pharmacist-led deprescribing using STOPPFrail for older adults in nursing homes. Int J Clin Pharm. 2024;46:1163\u201371.","journal-title":"Int J Clin Pharm"},{"key":"1889_CR14","doi-asserted-by":"publisher","first-page":"957","DOI":"10.1007\/s11096-024-01732-y","volume":"46","author":"C O\u2019Mahony","year":"2024","unstructured":"O\u2019Mahony C, Dalton K, O\u2019Hagan L, et al. Economic cost-benefit analysis of person-centred medicines reviews by general practice pharmacists. Int J Clin Pharm. 2024;46:957\u201365.","journal-title":"Int J Clin Pharm"},{"key":"1889_CR15","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-047515","volume":"11","author":"GB Gebretekle","year":"2021","unstructured":"Gebretekle GB, Mariam DH, Mac S, et al. Cost-utility analysis of antimicrobial stewardship programme at a tertiary teaching hospital in Ethiopia. BMJ Open. 2021;11: e047515.","journal-title":"BMJ Open"},{"key":"1889_CR16","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s40545-020-00272-w","volume":"13","author":"K Hussain","year":"2020","unstructured":"Hussain K, Khan MF, Ambreen G, et al. An antibiotic stewardship program in a surgical ICU of a resource-limited country: financial impact with improved clinical outcomes. J Pharm Policy Pract. 2020;13:69.","journal-title":"J Pharm Policy Pract"},{"key":"1889_CR17","doi-asserted-by":"publisher","first-page":"605","DOI":"10.5414\/CP202334","volume":"53","author":"J Wang","year":"2015","unstructured":"Wang J, Dong M, Lu Y, et al. Impact of pharmacist interventions on rational prophylactic antibiotic use and cost saving in elective cesarean section. Int J Clin Pharmacol Ther. 2015;53:605\u201315.","journal-title":"Int J Clin Pharmacol Ther"},{"key":"1889_CR18","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1007\/s10096-017-3166-6","volume":"37","author":"L Leache","year":"2018","unstructured":"Leache L, Aquerreta I, Aldaz A, et al. Evidence of clinical and economic impact of pharmacist interventions related to antimicrobials in the hospital setting. Eur J Clin Microbiol Infect Dis. 2018;37:799\u2013822.","journal-title":"Eur J Clin Microbiol Infect Dis"},{"key":"1889_CR19","doi-asserted-by":"publisher","DOI":"10.1200\/PO.24.00026","volume":"8","author":"G Srkalovic","year":"2024","unstructured":"Srkalovic G, Rothe M, Mangat PK, et al. Talazoparib in patients with solid tumors with BRCA1\/2 mutation: results from the targeted agent and profiling utilization registry study. JCO Precis Oncol. 2024;8: e2400026.","journal-title":"JCO Precis Oncol"},{"key":"1889_CR20","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/NEJMoa2206913","volume":"387","author":"MJ Dickinson","year":"2022","unstructured":"Dickinson MJ, Carlo-Stella C, Morschhauser F, et al. Glofitamab for relapsed or refractory diffuse large B-Cell lymphoma. N Engl J Med. 2022;387:2220\u201331.","journal-title":"N Engl J Med"},{"key":"1889_CR21","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa0910812","volume":"364","author":"TJ Louie","year":"2011","unstructured":"Louie TJ, Miller MA, Mullane KM, et al. Fidaxomicin versus vancomycin for clostridium difficile infection. N Engl J Med. 2011;364:422\u201331.","journal-title":"N Engl J Med"},{"key":"1889_CR22","doi-asserted-by":"publisher","first-page":"S136","DOI":"10.1086\/428054","volume":"41","author":"SL Davis","year":"2005","unstructured":"Davis SL, Delgado G Jr, McKinnon PS. Pharmacoeconomic considerations associated with the use of intravenous-to-oral moxifloxacin for community-acquired pneumonia. Clin Infect Dis. 2005;41:S136\u201343.","journal-title":"Clin Infect Dis"},{"key":"1889_CR23","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1186\/s12913-018-3306-4","volume":"18","author":"Z Bao","year":"2018","unstructured":"Bao Z, Ji C, Hu J, et al. Clinical and economic impact of pharmacist interventions on sampled outpatient prescriptions in a Chinese teaching hospital. BMC Health Serv Res. 2018;18:519.","journal-title":"BMC Health Serv Res"},{"key":"1889_CR24","doi-asserted-by":"publisher","first-page":"978","DOI":"10.2146\/ajhp170285","volume":"75","author":"GD Moore","year":"2018","unstructured":"Moore GD, Kosirog ER, Vande Griend JP, et al. Expansion of clinical pharmacist positions through sustainable funding. Am J Health Syst Pharm. 2018;75:978\u201381.","journal-title":"Am J Health Syst Pharm"},{"key":"1889_CR25","doi-asserted-by":"publisher","first-page":"e278","DOI":"10.1016\/S2214-109X(21)00517-9","volume":"10","author":"S Su","year":"2022","unstructured":"Su S, Wong WC, Zou Z, et al. Cost-effectiveness of universal screening for chronic hepatitis B virus infection in China: an economic evaluation. Lancet Glob Health. 2022;10:e278\u201387.","journal-title":"Lancet Glob Health"},{"key":"1889_CR26","doi-asserted-by":"publisher","first-page":"1448","DOI":"10.1016\/j.cmi.2021.04.004","volume":"27","author":"J Chen","year":"2021","unstructured":"Chen J, Gong CL, Hitchcock MM, et al. Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection. Clin Microbiol Infect. 2021;27:1448\u201354.","journal-title":"Clin Microbiol Infect"},{"key":"1889_CR27","doi-asserted-by":"publisher","first-page":"550.e1","DOI":"10.1016\/j.ajog.2021.08.014","volume":"225","author":"R Wang","year":"2021","unstructured":"Wang R, LaSala C. Role of antibiotic resistance in urinary tract infection management: a cost-effectiveness analysis. Am J Obstet Gynecol. 2021;225:550.e1\u2013550.e10.","journal-title":"Am J Obstet Gynecol"},{"key":"1889_CR28","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1186\/s12913-024-10883-7","volume":"24","author":"R Takaya","year":"2024","unstructured":"Takaya R, Mori N, Saito E, et al. Cost-effectiveness analysis of CTZ\/TAZ for the treatment of ventilated hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia in Japan. BMC Health Serv Res. 2024;24:389.","journal-title":"BMC Health Serv Res"},{"key":"1889_CR29","doi-asserted-by":"publisher","DOI":"10.2217\/cer-2022-0113","volume":"12","author":"J Naik","year":"2023","unstructured":"Naik J, Dillon R, Massello M, et al. Cost-effectiveness of imipenem\/cilastatin\/relebactam for hospital-acquired and ventilator-associated bacterial pneumonia. J Comp Eff Res. 2023;12: e220113.","journal-title":"J Comp Eff Res"},{"key":"1889_CR30","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S1473-3099(17)30751-X","volume":"18","author":"B Guery","year":"2018","unstructured":"Guery B, Menichetti F, Anttila VJ, et al. Extended-pulsed fidaxomicin versus vancomycin for Clostridium difficile infection in patients 60 years and older (EXTEND): a randomised, controlled, open-label, phase 3b\/4 trial. Lancet Infect Dis. 2018;18:296\u2013307.","journal-title":"Lancet Infect Dis"},{"key":"1889_CR31","doi-asserted-by":"publisher","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision modelling for health economic evaluation","author":"A Briggs","year":"2006","unstructured":"Briggs A, Sculpher M, Claxton K. Decision modelling for health economic evaluation. New York: Oxford University Press; 2006. ISBN: 9780198526629."},{"key":"1889_CR32","doi-asserted-by":"publisher","first-page":"ofad116","DOI":"10.1093\/ofid\/ofad116","volume":"10","author":"K Sawada","year":"2023","unstructured":"Sawada K, Inose R, Goto R, et al. Effectiveness of noncertified pharmacist-led antimicrobial stewardship programs in a medium-sized hospital without an infectious disease specialist: a retrospective pre-post study. Open Forum Infect Dis. 2023;10:ofad116.","journal-title":"Open Forum Infect Dis"},{"key":"1889_CR33","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/s40780-018-0125-z","volume":"4","author":"Y Tasaka","year":"2018","unstructured":"Tasaka Y, Tanaka A, Yasunaga D, et al. Potential drug-related problems detected by routine pharmaceutical interventions: safety and economic contributions made by hospital pharmacists in Japan. J Pharm Health Care Sci. 2018;4:33.","journal-title":"J Pharm Health Care Sci"},{"key":"1889_CR34","doi-asserted-by":"publisher","first-page":"1242779","DOI":"10.3389\/fphar.2023.1242779","volume":"14","author":"N Yal\u00e7\u0131n","year":"2023","unstructured":"Yal\u00e7\u0131n N, Ka\u015f\u0131kc\u0131 M, \u00c7elik HT, et al. Impact of clinical pharmacist-led intervention for drug-related problems in neonatal intensive care unit a randomized controlled trial. Front Pharmacol. 2023;14:1242779.","journal-title":"Front Pharmacol"},{"key":"1889_CR35","doi-asserted-by":"publisher","first-page":"1005150","DOI":"10.3389\/fcvm.2022.1005150","volume":"4","author":"P Sreepathy","year":"2022","unstructured":"Sreepathy P, Kim YJ, Ahuja Z, et al. The association between implementation of multidisciplinary rounds and clinical outcomes. Front Cardiovasc Med. 2022;4:1005150.","journal-title":"Front Cardiovasc Med"},{"key":"1889_CR36","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1093\/ajhp\/zxac107","volume":"79","author":"K Jantarathaneewat","year":"2022","unstructured":"Jantarathaneewat K, Montakantikul P, Weber DJ, et al. Impact of an infectious diseases pharmacist-led intervention on antimicrobial stewardship program guideline adherence at a Thai medical center. Am J Health Syst Pharm. 2022;79:1266\u201372.","journal-title":"Am J Health Syst Pharm"}],"container-title":["International Journal of Clinical Pharmacy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01889-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11096-025-01889-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11096-025-01889-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T06:36:54Z","timestamp":1748587014000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11096-025-01889-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,20]]},"references-count":36,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["1889"],"URL":"https:\/\/doi.org\/10.1007\/s11096-025-01889-0","relation":{},"ISSN":["2210-7703","2210-7711"],"issn-type":[{"type":"print","value":"2210-7703"},{"type":"electronic","value":"2210-7711"}],"subject":[],"published":{"date-parts":[[2025,3,20]]},"assertion":[{"value":"23 November 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Authors declare no conflicts of interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}